e-learning
resources
Munich 2014
Sunday, 07.09.2014
Prevalence of COPD and mortality from COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists
S. Cascini, U. Kirchmayer, N. Agabiti, M. Di Martino, G. Formoso, C. Voci, R. Pistelli, E. Patorno, M. Davoli, OUTPUL Study Group (Rome, Bologna, Italy; Boston, United States Of America)
Source:
International Congress 2014 – Prevalence of COPD and mortality from COPD
Session:
Prevalence of COPD and mortality from COPD
Session type:
Thematic Poster Session
Number:
1076
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Cascini, U. Kirchmayer, N. Agabiti, M. Di Martino, G. Formoso, C. Voci, R. Pistelli, E. Patorno, M. Davoli, OUTPUL Study Group (Rome, Bologna, Italy; Boston, United States Of America). One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists. Eur Respir J 2014; 44: Suppl. 58, 1076
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Related content which might interest you:
Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016
Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality?
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Estimation of tiotropium efficacy at the COPD patients with group D
Source: International Congress 2015 – Different data in COPD
Year: 2015
Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014
Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Long-term inhaled corticosteroid use in COPD and the risk of fracture in men and women
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept